We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Takeda has elected to accelerate the transition of development responsibility for Finch Therapeutics' FIN-524, an investigational oral microbiome therapy in development for ulcerative colitis.